What is B. Riley’s Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Stock analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a research note issued on Wednesday, November 13th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings per share of ($0.25) for the quarter. B. Riley currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.06) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS.

Wave Life Sciences (NASDAQ:WVE) last issued its earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.19). The company had revenue of ($7.68) million during the quarter, compared to the consensus estimate of $15.45 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Several other analysts also recently weighed in on the company. Royal Bank of Canada upped their price target on Wave Life Sciences from $7.00 to $15.00 and gave the stock a “sector perform” rating in a research note on Monday, October 21st. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday. StockNews.com cut Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday. JPMorgan Chase & Co. raised their target price on Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, October 17th. Finally, Truist Financial increased their price target on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.89.

Wave Life Sciences Price Performance

NASDAQ:WVE opened at $15.00 on Friday. The business has a 50 day moving average of $10.40 and a 200 day moving average of $7.41. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -13.51 and a beta of -1.20. Wave Life Sciences has a 1-year low of $3.50 and a 1-year high of $16.74.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP acquired a new stake in shares of Wave Life Sciences in the 3rd quarter worth $2,821,000. Maverick Capital Ltd. lifted its stake in shares of Wave Life Sciences by 31.0% in the 3rd quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock worth $82,390,000 after acquiring an additional 2,378,159 shares during the period. Walleye Capital LLC acquired a new stake in shares of Wave Life Sciences in the third quarter valued at about $4,940,000. Martingale Asset Management L P lifted its stake in shares of Wave Life Sciences by 25.6% in the third quarter. Martingale Asset Management L P now owns 111,199 shares of the company’s stock valued at $912,000 after purchasing an additional 22,652 shares during the period. Finally, Glenmede Trust Co. NA raised its position in Wave Life Sciences by 71.1% during the third quarter. Glenmede Trust Co. NA now owns 39,075 shares of the company’s stock worth $320,000 after acquiring an additional 16,235 shares during the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Wave Life Sciences

In other news, CFO Kyle Moran sold 17,146 shares of the firm’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the sale, the chief financial officer now directly owns 19,777 shares in the company, valued at approximately $177,993. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Bolno sold 48,366 shares of the firm’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $5.78, for a total transaction of $279,555.48. Following the completion of the sale, the chief executive officer now owns 359,059 shares in the company, valued at $2,075,361.02. The trade was a 11.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 400,822 shares of company stock worth $5,221,768. 29.10% of the stock is currently owned by insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.